Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

Phase II, single-arm, open-label single center study that assess clinical feasibility and safety of 3 cycles neoadjuvant Toripalimab plus chemotherapy in rare mutations stage IIB-IIIB NSCLC followed by optional adjuvant treatment upon investigators' decisions.

NCT Number	NCT05800340
Lead Sponsor	Guangdong Provincial People's Hospital Collaborators: Shanghai Junshi Bioscience Co., Ltd.
Conditions	Non-Small Cell Lung Cancer, RET Driver Mutation, BRAF V600 Mutation, Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation, MET Amplification, MET Exon 14 Skipping Mutation
Enrollment	30 participants
Start Date	2023-04-04
Primary Completion	2024-12-31 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2023-04-05